Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
BUZZ—US chip-related stocks rebound from recent plunge

BUZZ—US chip-related stocks rebound from recent plunge

路透社路透社2026/10/19 11:42
Show original

- **After experiencing a round of broad sell-offs since October 7 (link), the stock prices of US chip-related companies rose in pre-market trading

** Rising Treasury yields and concerns about Federal Reserve rate hikes may increase borrowing costs and dampen spending on artificial intelligence infrastructure

** Chip giant NVIDIA NVDA.O rose 1.44%, and peer Advanced Micro Devices AMD.O climbed 3.22%

** Neocloud company Coreweave CRWV.O, backed by NVIDIA, surged about 3% today after plunging more than 25% last week

** Broadcom (AVGO.O) rose, while Qualcomm (QCOM.O) was up about 2.5%

** Marvell (MRVL.O) and Intel (INTC.O) both rose about 4%

** Memory chipmaker Micron Technology MU.O rose 3.34%

** Data storage company Western Digital WDC.O was up 2.67%, and SanDisk SNDK.O rose 4.06%

** As of the close of the previous trading day, the Philadelphia Semiconductor Index .SOX has risen 57.24% year-to-date; in the past two weeks, the index has fallen over 15%


(To facilitate non-native English speakers, Reuters provides automated translations of its reports in several other languages. Since automated translation may contain errors or lack required context, Reuters does not guarantee the accuracy of automated translation texts, which are provided solely for reader convenience. Reuters accepts no responsibility for any damage or loss caused by the use of automated translation features.)

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Amgen's Imdelltra has maintained data with an HR of 0.42, nearly doubling survival time. Morgan Stanley estimates that it will become a single product with annual sales of around 5 billions USD. However, they maintain a Neutral rating and a target price of 350 USD.

智通财经•2026/10/26 04:20
A $5 billion single-product emerges? JPMorgan maintains a "Neutral" rating on Amgen (AMGN.US): A good drug doesn't necessarily mean a good buying opportunity.

Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks

Goldman Sachs stated that the Japanese yen has become a better tool for hedging against AI shocks, with policy shifts reducing the risk of depreciation. The bank recommends shorting USD/JPY and EUR/JPY.

智通财经•2026/10/26 03:41
Goldman Sachs: Yen Regains "Safe Haven King" Status, Becomes Most Effective Tool to Hedge Against AI Market Shocks